Study of a new drug for psychosis in people with Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests an experimental medication to reduce hallucinations and delusions in people who have Alzheimer's disease. It may help manage these symptoms and improve quality of life for patients and their caregivers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosis of Alzheimer's disease, confirmed by a blood test, spinal fluid test, or brain scan
- Experiencing hallucinations or delusions (seeing or hearing things that aren't there, or false beliefs)
- Symptoms must be moderate to severe, with a score of at least 4 on a scale measuring overall severity
- Have a Mini-Mental State Exam (MMSE-2) score between 6 and 24 (inclusive)
- Must have a caregiver (family member, friend, or professional) who can provide support
- No other major mental health conditions like schizophrenia or bipolar disorder
- Not currently taking certain psychiatric medications that could interfere
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
This study looks at “tau” (a brain protein) and brain-signal patterns in people with Alzheimer’s disease who have psychotic symptoms like hallucinations or delusions. It may help researchers understand what’s happening in the brain and how to better target these symptoms.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This study tests an experimental medication, ITI-1284, to see if it can safely reduce agitation in people with Alzheimer's disease. Agitation can include restlessness, aggression, or irritability, and this drug aims to help manage those symptoms.
Hear when a new Psychotic Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.